Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

By S. Giacchetti, B. Perpoint, R. Zidani, N. Bail, R. Faggiuolo, C. Focan, P. Chollet, J. Llory, Y. Létourneau, B. Coudert and 7 more. Journal of Clinical Oncology, 2000

1,434 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/cb6fdda12aa4b32b2864ff7ed75900f1ab2e8b5e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Guido Kroemer
2. L. Galluzzi
3. Oliver Kepp
4. M. Castedo
5. L. Zitvogel
6. Rebecca S. Y. Wong

Citations in the corpus

• Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. (2007, methodology): “efficacy compared with FU/LV alone in randomized studies.(2-6) These data have established that in”
• [Systemic therapy for colorectal cancer]. (2005, background): “The benefit of adding oxaliplatin to LV/5FU in the first-line therapy for patients with metastatic colorectal cancer has been demonstrated in two large international, multicentre, randomized phase III trials (24).”
• Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. (2004, background): “Expanding the body of data gathered indicates that in metastatic disease, this combined strategy might be beneficial on the overall rate of recurrence [7, 8, 10, 11].”
• Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? (2004, result): “The median survival of 30 months in our study population also compares favorably to that of 20 months observed with the currently most effective chemotherapy regimens alone.(15,26) However, the overall survival rate was lower than the 51% 5-year survival of our patients resected for less than 4 meta”
• Molecular mechanisms of cisplatin resistance (2012, background): “Oxaliplatin is currently employed against colorectal cancer in association with 5-fluorouracil and folinic acid (the so-called FOLFOX protocol) (Giacchetti et al., 2000; de Gramont et al., 2000; Rothenberg et al., 2003; Goldberg et al., 2004), and may also be useful for the treatment of lung cancer ”